NCT03416192

Brief Summary

The medium cut-off dialysis (MCO) membrane has been developed to improve middle molecule removal compared to standard high-flux dialysis filters. The aim of this study is to compare levels of middle molecules after 12 weeks of MCO hemodialysis, compared to 12 weeks of hemodiafiltration using standard high-flux filter.

Trial Health

15
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Feb 2019

Shorter than P25 for not_applicable

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 23, 2018

Completed
8 days until next milestone

First Posted

Study publicly available on registry

January 31, 2018

Completed
1 year until next milestone

Study Start

First participant enrolled

February 1, 2019

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2019

Completed
Last Updated

April 15, 2020

Status Verified

April 1, 2020

Enrollment Period

10 months

First QC Date

January 23, 2018

Last Update Submit

April 14, 2020

Conditions

Keywords

DialysisMCOMiddle molecules

Outcome Measures

Primary Outcomes (2)

  • Comparison of predialysis mean of middle molecules after 12 weeks (Beta-2-microglobulin, Cystatin C, Myoglobin, Beta-Trace Protein, Troponin T, Prealbumin).

    12 weeks

  • Comparison of postdialysis mean of middle molecules after 12 weeks (Beta-2-microglobulin, Cystatin C, Myoglobin, Beta-Trace Protein, Troponin T, Prealbumin).

    12 weeks

Secondary Outcomes (7)

  • Comparison of predialysis mean of small molecules (CRP, Urea, Phosphate and Creatinine) after 12 weeks.

    12 weeks

  • Comparison of postdialysis mean of of small molecules (CRP, Urea, Phosphate and Creatinine) after 12 weeks.

    12 weeks

  • Comparison of predialysis mean of large molecules after 12 weeks (Albumin, Transferrin, IgG).

    12 weeks

  • Comparison of postdialysis mean of large molecules after 12 weeks (Albumin, Transferrin, IgG).

    12 weeks

  • Comparison of pre- and postdialysis mean of all molecules at 0, 4 and 8 weeks.

    8 weeks

  • +2 more secondary outcomes

Study Arms (2)

MCO-HD

EXPERIMENTAL

Hemodialysis with Medium Cut-Off filter

Device: MCO-HDDevice: high-flux HDF

High-flux HDF

ACTIVE COMPARATOR

Hemodiafiltration with standard high-flux filter

Device: MCO-HDDevice: high-flux HDF

Interventions

MCO-HDDEVICE

Measurements will be done after 0,4,8 and 12 weeks of hemodialysis with Medium Cut-Off filter.

High-flux HDFMCO-HD

Measurements will be done after 0,4,8 and 12 weeks of hemodiafiltration with standard high-flux filter

High-flux HDFMCO-HD

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Ongoing HDF treatment (\>3 months)
  • Oliguric
  • Albumin ≥ 30
  • CRP \<15
  • No acute myocardial infarction within 3 months.
  • Swedish or english speaking.

You may not qualify if:

  • \- Not able to understand the study information.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Renal Insufficiency, ChronicUremia

Condition Hierarchy (Ancestors)

Renal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Anders Christensson, MD, PhD

    Region Skane, Lund University

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 23, 2018

First Posted

January 31, 2018

Study Start

February 1, 2019

Primary Completion

December 1, 2019

Study Completion

December 1, 2019

Last Updated

April 15, 2020

Record last verified: 2020-04

Data Sharing

IPD Sharing
Will not share